ClinicalTrials.Veeva

Menu
E

Eastern Shore Research Institute, LLC | Fairhope, AL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

sodium
R2R01
Obicetrapib
Inclisiran
EVOLocumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 8 total trials

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The primary purpose of this clinical trial is to compare the effects of study medicine (Ponsegromab/PF-06946860) with a placebo (an injection that lo...

Enrolling
Heart Failure
Drug: Optional Cohort C: Ponsegromab low dose
Other: Optional Cohort C: Matched placebo

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Obicetrapib
Drug: Placebo

The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipi...

Active, not recruiting
Stroke
Myocardial Infarction
Drug: Evolocumab
Drug: Routine Lipid Management

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

This Study Aims to Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening H...

Enrolling
Worsening Heart Failure (WHF)
Heart Failure
Drug: R2R01
Drug: Placebo

Trial sponsors

Novartis logo
Pfizer logo
Amgen logo
C
N
R

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems